<DOC>
	<DOCNO>NCT00316953</DOCNO>
	<brief_summary>This phase I trial study side effect best dose dasatinib treat young patient recurrent refractory solid tumor Philadelphia chromosome-positive acute lymphoblastic leukemia chronic myelogenous leukemia respond imatinib mesylate . Dasatinib may stop growth cancer cell block enzymes need cell growth</brief_summary>
	<brief_title>Dasatinib Treating Young Patients With Recurrent Refractory Solid Tumors Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia That Did Not Respond Imatinib Mesylate</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine toxicity estimate maximum tolerate dose recommend phase 2 dose dasatinib pediatric patient refractory solid tumor . II . Determine toxicities dasatinib pediatric patient imatinib mesylate-resistant Philadelphia chromosome-positive ( Ph+ ) leukemia . III . Characterize pharmacokinetics dasatinib pediatric patient refractory solid tumor imatinib-resistant Ph+ leukemia . SECONDARY OBJECTIVES : I. Preliminarily define antitumor activity dasatinib pediatric patient refractory solid tumor within confines phase I study . II . Obtain pilot data activity dasatinib administer pediatric patient Ph+ leukemia . III . Assess biologic activity dasatinib tumor cell available . IV . Determine phosphotyrosine state SRC ABL substrates correlate dasatinib dosage antitumor activity ( pharmacodynamics study ) . OUTLINE : This multicenter , dose-escalation study . Patients stratify accord disease ( solid tumor vs leukemia ) . Stratum 1 ( solid tumor ) : Patients receive oral dasatinib twice daily day 1-28 . Treatment repeat every 28 day 24 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos dasatinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede ≥ 2 6 patient experience dose-limiting toxicity ( DLT ) . Stratum 2 ( leukemia ) : Patients receive dasatinib stratum 1 . Cohorts 3-12 patient receive escalate de-escalating dos dasatinib . The MTD define dose precede 7 12 patient experience DLT . After complete study treatment , patient follow 1 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Histologically confirm diagnosis 1 following : Malignant extracranial solid tumor Recurrent refractory disease Known bone marrow metastases* allow Imatinib mesylateresistant Philadelphia chromosomepositive ( Ph+ ) acute lymphoblastic leukemia ( ALL ) , define M3 bone marrow patient previously receive imatinib mesylatecontaining treatment regimen Imatinib mesylateresistant Ph+ chronic myelogenous leukemia ( CML ) , define follow : Increasing WBC platelet count imatinib mesylate therapy Lack cytogenetic response adequate duration imatinib mesylate therapy , define 1 follow : Failed achieve complete hematologic response completion 3 month imatinib mesylate treatment Failed achieve partial complete cytogenetic response ( i.e. , ≤ 35 % Ph+ cell ) 6 month imatinib mesylate treatment Appearance accelerate blastic feature imatinib mesylate therapy Reappearance Ph+ clone initial complete cytogenetic response imatinib mesylate More 30 % increase Ph+ cell peripheral blood bone marrow cytogenetics imatinib mesylate therapy Imatinib mesylate intolerance , define development adverse effect require discontinuation imatinib mesylate therapy Measurable disease ( patient CML ALL ) Determined hematologic , cytogenetic , molecular study CML Determined bone marrow blast percentage ALL Measurable evaluable disease ( patient solid tumor ) No know curative therapy survivalprolonging therapy acceptable quality life No CNS solid tumor CNSpositive leukemia allow Karnofsky performance status ( PS ) ≥ 50 % ( patient &gt; 10 year age ) Lansky PS ≥ 50 % ( patient ≤ 10 year age ) No evidence graftvshost disease Solid tumor : Absolute neutrophil count ≥ 1,000/mm^3 ( 750/mm^3 bone marrow infiltration ) Platelet count ≥ 100,000/mm^3 ( transfusion independent ) ( 50,000/mm^3 bone marrow infiltration ) Hemoglobin ≥ 8.0 g/dL ( red blood cell [ RBC ] transfusion allow ) ALL/CML : Platelet count ≥ 20,000/mm^3 ( platelet transfusion allow ) Hemoglobin ≥ 8.0 g/dL ( RBC transfusion allow ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine base age , follow : No great 0.6 mg/dL ( 123 month age ) No great 0.8 mg/dL ( 2 5 year age ) No great 1.0 mg/dL ( 69 year age ) No great 1.2 mg/dL ( 1012 year age ) No great 1.4 mg/dL ( 13 year age [ female ] ) No great 1.5 mg/dL ( 1315 year age [ male ] ) No great 1.7 mg/dL ( 16 year age [ male ] ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 110 U/L Albumin ≥ 2 g/dL Normal 12lead EKG correct QTc &lt; 450 msec AND meet 1 follow criterion : Shortening fraction normal Ejection fraction normal No evidence dyspnea rest No exercise intolerance Pulse oximetry &gt; 94 % clinical indication determination Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No swallowing dysfunction would prevent take oral liquid medication See Disease Characteristics Recovered prior chemotherapy , immunotherapy , radiotherapy No myelosuppressive chemotherapy within past 3 week ( 6 week nitrosoureas ) At least 7 day since prior growth factor At least 14 day since prior pegfilgrastim At least 7 day since prior biologic agent At least 2 week since prior local smallport palliative radiotherapy At least 3 month since prior totalbody irradiation , craniospinal radiation , radiation ≥ 50 % pelvis At least 6 week since prior substantial bone marrow radiation At least 3 month since prior stem cell transplantation Hydroxyurea cytoreduction Ph+ leukemia allow provide discontinue 24 hour first dose dasatinib Prior intrathecal ( IT ) therapy allow ( patient CNSpositive leukemia ) Concurrent IT therapy comprise hydrocortisone , cytarabine , methotrexate , cytarabine ( liposomal ) allow ( patient CNSpositive leukemia ) No concurrent investigational drug No concurrent anticancer agent , include chemotherapy , radiotherapy , immunotherapy , biologic therapy No concurrent enzymeinducing anticonvulsant , include follow : Phenytoin Phenobarbital Carbamazepine Felbamate Primdone Oxcarbazepine No concurrent antithrombotic antiplatelet agent , include follow : Warfarin Heparin Lowmolecular weight heparin Aspirin Ibuprofen Other nonsteroidal antiinflammatory drug No concurrent CYP3A4 inhibitor , include itraconazole , ketoconazole , voriconazole No concurrent highly active antiretroviral treatment HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>